Tscan Therapeutics Profit Margin

The latest profit margin for TCRX is -2558.96% as of June 2026. That compares with -1964.88% in the prior-year period — down 30.2% year over year. That is below the Healthcare sector average of 13.45%. Investors often review this figure alongside Tscan Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, TCRX's profit margin moved from -1964.88% to -2558.96% — a 30.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Tscan Therapeutics's valuation or profitability profile.

Against Healthcare companies, TCRX currently prints -2558.96% for profit margin, while the sector average sits near 13.45%. That is roughly 19128.8% below the sector mean. Large gaps often invite a closer look at Tscan Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Tscan Therapeutics converts resources into returns. At -2558.96%, TCRX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1964.88% in the prior-year period — down 30.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TCRX's profit margin (-2558.96%), review year-over-year change from -1964.88%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.